UKUluvitike G. I. U. Kariyawasam

Uluvitike G. I. U. Kariyawasam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uluvitike G. I. U. Kariyawasam has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial

    by Katrin M. Sjoquist, Alexander Dobrovic, Kristy P. Robledo, Ksenija Nesic, Sally Baron-Hay, Sumitra Ananda, Nicole McCarthy, Jeffrey Goh, Christopher Steer, Nick Murray, et al.

    Background: Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (me BRCA1 ) or RAD51C (me RAD51C ) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD. Methods: Single-arm phase 2 trial of olaparib 300 mg orally twice daily. Tumour me BRCA1/ me RAD51C determined by methylation-sensitive, high-resolution melting PCR and targeted sequencing. Unmethylated cases underwent HR gene mutation testing. Primary outcome: objective tumour response rate (OTRR) at 6 months(m). Secondary outcomes: progression-free survival (PFS), OTRR according to HR gene aberration, and safety. Results: Total 22 enrolled: promoter methylation detected in 8/15 HGSOC and 5/7 TNBC, and pathogenic variants (PV) in non- BRCA HR genes. OTRR at 6 m was 40% HGSOC and 0% TNBC. OTRR was 38% in methylated cases vs 43% for other HRD. 6 m/12 m PFS were 53% / 25% (HGSOC), and 17% / 0% (TNBC). Conclusions: Olaparib demonstrated activity in HGSOC beyond gBRCAm, including with me BRCA1 or gRAD51C PV. Olaparib had limited activity in pre-treated TNBC. Effects of prior chemotherapy on me BRCA1/ me RAD51C require exploration to improve patient selection for PARPi. Clinical trials registration: Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.

  • Open Access

    Growth hormone (GH) mutations and sequence variants in children with growth hormone deficiency (GHD)

    by Uluvitike G. I. U. Kariyawasam, Faiz M. M. T. Marikar

    Background. Isolated growth hormone deficiency (IGHD) exhibits genetic hete­rogeneity in both familial and sporadic cases. The GH1 gene is a mutational hotspot among the five genes responsible for growth hormone deficiency (GHD), frequently causing short stature. The study aimed to screen for two common GH1 gene mutations prevalent in Asian populations among Sri Lankan children with biochemically confirmed GHD, and to compare sequence variations with known variants in other populations. Methods. Genomic DNA was extracted from 10 children with confirmed GHD attending Lady Ridgeway Hospital, Colombo. PCR amplification was optimized for two primer sets targeting hotspot regions: the deletion-prone homologous flanking regions and the exon 3-intron 3-exon 4 region. Restriction fragment length polymorphism (RFLP) analysis was performed using SmaI enzyme (to detect the common 6.7 kb deletion) and NlaIII enzyme (to detect the G>A transition at the intron 3 splice donor site). Direct DNA sequencing was subsequently conducted for variant confirmation. Results. SmaI digestion revealed heterozygous-like patterns in 3 out of 10 samples (30 %); it reflects heterozygosity or residual allele abnormalities. The remaining 7 samples (70 %) showed banding patterns identical to healthy controls. NlaIII digestion showed no mutations in any of the 10 samples (0/10, 0 %), with all patient samples displaying patterns indistinguishable from healthy DNA. Conclusion. The two mutations commonly found in Asian populations were largely absent in this Sri Lankan cohort, suggesting that short stature in this population may result from alternative GH1 mutations or other genetic variants, warranting comprehensive genomic screening studies.

  • Open Access

    Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

    by Chee Khoon Lee, Apriliana E. R. Kartikasari, Nirashaa T. Bound, Katherine E. Francis, Kristy Shield-Artin, Justin Bedo, Ksenija Nesic, Katrina Diamante, Rachel L. O’cOnnell, Mutsa Madondo, et al.

    SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines. Priming with olaparib, or cyclophosphamide-olaparib, followed by durvalumab-olaparib, are both associated with longer PFS compared to olaparib monotherapy, but do not reach the pre-specified primary endpoint of 36-week trial threshold (PFS36). PFS36 rates are 47.4% (95% CI, 31.0-62.1; olaparib priming then olaparib-durvalumab), 48.7% (32.5-63.2; olaparib-cyclophosphamide then olaparib-durvalumab) and 35.1% (20.4-50.3; olaparib monotherapy). PFS is significantly longer for the homologous recombination deficient (N = 71) as compared to the proficient (HRP) (N = 29) subgroups (Hazard Ratio (HR) 0.55, 0.35-0.87). CUP-CC+ subgroup (N = 58) has a significantly longer PFS (HR 0.31, 0.19-0.49) than CUP-CC- (N = 46). Future studies should investigate whether CUP-CC has the potential to personalize poly (ADP-ribose) polymerase inhibitor therapies for patients who are BRCA wild-type, including HRP patients.


  • Open Access

    The Frequency and Spectrum of Chromosomal Translocations in a Cohort of Sri Lankans

    by Chamara S. Paththinige, Nirmala D. Sirisena, U. G. I. U. Kariyawasam, Vajira H. W. Dissanayake

    Translocations are the most common type of structural chromosomal abnormalities. Unbalanced translocations are usually found in children who present with congenital abnormalities, developmental delay, or intellectual disability. Balanced translocations are usually found in adults who frequently present with reproductive failure; either subfertility, or recurrent pregnancy loss. Herein, we report the spectrum and frequency of translocations in a Sri Lankan cohort. A database of patients undergoing cytogenetic testing was maintained prospectively from January 2007 to December 2016 and analyzed, retrospectively. A total of 15,864 individuals were tested. Among them, 277 (1.7%) had translocations. There were 142 (51.3%) unbalanced translocations and 135 (48.7%) balanced translocations. Majority (160; 57.8%) were Robertsonian translocations. There were 145 (52.3%) children and adolescents aged less than 18 years with translocations, and 142 (97.9%) were unbalanced translocations. Majority [138 (95.2%)] were referred due to congenital abnormalities, developmental delay, or intellectual disability, and 91 were children with translocation Down syndrome. All adults aged 18 years or above (132) had balanced translocations. Subfertility and recurrent pregnancy loss [84 (63.6%)] and offspring(s) with congenital abnormalities [48 (36.4%)] were the most common indications in this group. Majority (68.2%) in this group were females with reciprocal translocations (55.3%). Chromosomes 21, 14, and 13 were the most commonly involved with rob(14q21q) [72 (26%)], rob(21q21q) [30 (13.7%)], and rob(13q14q) [34 (12.3%)] accounting for 52% of the translocations. Chromosomes 1, 8, 11, and 18 were most commonly involved in reciprocal translocations. The observed high frequency of chromosomal translocations in our cohort highlights the importance of undertaking cytogenetic evaluation and providing appropriate genetic counseling for individuals with the phenotypes associated with these translocations.


  • Open Access

    Ring Chromosome 4 in a Child with Multiple Congenital Abnormalities: A Case Report and Review of the Literature

    by C. S. Paththinige, N. D. Sirisena, U. G. I. U. Kariyawasam, L. P. C. Saman Kumara, V. H. W. Dissanayake

    A female child born preterm with intrauterine growth retardation and presenting with facial dysmorphism with clefts, microcephaly, limb deformities, and congenital abnormalities involving cardiovascular and urinary systems is described. Chromosomal analysis showed ade novo46,XX,r(4)(p15.3q35) karyotype. The clinical features of the patient were compared with the phenotypic characteristics of 17 previously reported cases with ring chromosome 4 and those with Wolf-Hirschhorn syndrome (4p-). Clinical features observed in this case are consistent with the consensus phenotype in ring chromosome 4. Patent ductus arteriosus and bilateral talipes equinovarus observed in this baby widen the phenotypic spectrum associated with ring chromosome 4.